Ligand Pharmaceuticals vs Maravai LifeSciences
LGND and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGND and MRVI compare
Ligand Pharmaceuticals is the larger company, worth 3.1 times as much as Maravai LifeSciences ($6.0B against $1.9B).
Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −5.0% for Maravai LifeSciences).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −37.1% at Maravai LifeSciences.
Maravai LifeSciences scores higher on the StockData Score (7 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGND | MRVI |
|---|---|---|
| Size and price | ||
| Market cap | $6.0B | $1.9B |
| Share price | $301.71 | $7.40 |
| Change, 1 year | 49.9% | 128% |
| Change, 5 years | 92.4% | −82.2% |
| Beta (5Y) | 0.80 | 0.29 |
| Employees | 47 | 435 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 132× | – |
| P/S | 23.8× | 9.2× (better) |
| P/B | 6.3× (better) | 9.4× |
| EV/EBITDA | 111× | – |
| P/FCF | 66.6× | – |
| FCF yield | 1.5% (better) | −1.9% |
| Fair value | $55.27 | $2.74 |
| Margin of safety | −446% | −170% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.0% (better) | −5.0% |
| Revenue growth, 5Y average | 10.4% (better) | −8.1% |
| Net income growth (TTM) | 5.9% | – |
| EPS growth (TTM) | 18.7% | – |
| Profitability | ||
| Gross margin | – | 34.9% |
| Operating margin | 10.1% (better) | −56.1% |
| Net margin | 20.3% (better) | −37.1% |
| FCF margin | 35.7% (better) | −17.2% |
| Return on equity | 5.4% (better) | −32.9% |
| Return on invested capital | 2.6% (better) | −32.4% |
| Financial health | ||
| Debt / equity | 1.17 | 0.72 (better) |
| Net debt / EBITDA | 11.26 | – |
| Interest coverage | 3.1× (better) | −4.9× |
| Current ratio | 1.22 | 4.05 (better) |
| Altman Z-score | 3.39 | 4.57 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 113% | 55.5% |
| Held by insiders | 2.6% | 3.6% |
| Insider net buying, 12 months | −$35.7M | $115K (better) |
| Short interest, % of float | – | 5.6% |
Go deeper
- LGND stock overview
- LGND income statement
- LGND valuation and score
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.